title: Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.
abstract: Somatostatin analogues inhibit in vitro cell proliferation via specific membrane receptors (SSTRs). Recent studies on transfected cell lines have shown a ligand-induced formation of receptor dimers. The aim of this study is 1) to evaluate the role of specific ligands in modulating receptor interactions in the androgen-dependent prostate cancer cell line, LNCaP, and in the non-small cell lung cancer line, Calu-6, by co-immunoprecipitation and immunoblot; and 2) to correlate the antiproliferative effect of these compounds with their ability in modulating receptor interactions. In LNCaP, we have demonstrated the constitutive presence of sstr₁/sstr₂, sstr₂/sstr₅, sstr₅/dopamine (DA) type 2 receptor (D₂R), and sstr₂/D₂R dimers. BIM-23704 (sstr₁- and sstr₂-preferential compound) increased the co-immunoprecipitation of sstr₁/sstr₂ and significantly inhibited proliferation (-30.98%). BIM-23244 (sstr₂-sstr₅ selective agonist) significantly increased the co-immunoprecipitation of sstr₂/sstr₅, and induced a -41.36% inhibition of proliferation. BIM-23A760, a new somatostatin/DA chimeric agonist with a high affinity for sstr₂ and D₂R and a moderate affinity for sstr₅, significantly increased the sstr₅/D₂R and sstr₂/D₂R complexes and was the most powerful in inhibiting proliferation (-42.30%). The chimeric compound was also the most efficient in modulating receptor interaction in Calu-6, increasing the co-immunoprecipitation of D₂R/sstr₅ and inhibiting cell proliferation (-30.54%). However, behind BIM-23A760, BIM-53097 (D₂R-preferential compound) also significantly inhibited Calu-6 proliferation (-17.71%), suggesting a key role for D₂R in receptor cross talk and in controlling cell growth. Indeed, activation of monomeric receptors did not affect receptor co-immunoprecipitation, whereas cell proliferation was significantly inhibited when the receptors were synergistically activated. In conclusion, our data show a dynamic ligand-induced somatostatin and DA receptor interaction, which may be crucial for the antiproliferative effects of the new analogues.
authors.affiliation: Department of Endocrinological and Medical Sciences and Center of Excellence for Biomedical Research, Università degli Studi di Genova, 16132 Genova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Arvigo
authors.forename: F
authors.initials: F
authors.lastname: Gatto
authors.forename: M
authors.initials: M
authors.lastname: Ruscica
authors.forename: P
authors.initials: P
authors.lastname: Ameri
authors.forename: E
authors.initials: E
authors.lastname: Dozio
authors.forename: M
authors.initials: M
authors.lastname: Albertelli
authors.forename: M D
authors.initials: MD
authors.lastname: Culler
authors.forename: M
authors.initials: M
authors.lastname: Motta
authors.forename: F
authors.initials: F
authors.lastname: Minuto
authors.forename: P
authors.initials: P
authors.lastname: Magni
authors.forename: D
authors.initials: D
authors.lastname: Ferone
mesh_terms: D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004298:Dopamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D047468:Immunoprecipitation; D008175:Lung Neoplasms / Q000378:metabolism*; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000032:analysis / Q000378:metabolism*; D017481:Receptors, Somatostatin / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*
chemical_list: C423390:BIM-23244; D017448:Receptors, Dopamine D2; D017481:Receptors, Somatostatin; D013004:Somatostatin; C531242:TBR-760; D004298:Dopamine